Literature DB >> 28697987

Update MRONJ and perspectives of its treatment.

P J Voss1, P Poxleitner1, R Schmelzeisen1, A Stricker1, W Semper-Hogg2.   

Abstract

Antiresorptive agents are widely used in catabolic bone diseases. Not only bisphosphonates but also new drugs like Denosumab may induce osteonecrosis of the jaw as a side effect. The present review describes the current effect mechanisms of commonly used antiresorptives, pathogenetic theories for the development of antiresorptive-related osteonecrosis of the jaw (ARONJ), and potential risk factors. Furthermore, diagnostic modalities and treatment options as well as new and innovative strategies are discussed. The major key factor to avoid the occurrence of ARONJ still remains the implementation of throughout preventive measures.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ARONJ; Bisphosphonates; Denosumab; Osteonecrosis of the jaw

Mesh：

Substances：

Year:  2017        PMID： 28697987     DOI： 10.1016/j.jormas.2017.06.012

Source DB:  PubMed          Journal:  J Stomatol Oral Maxillofac Surg        ISSN： 2468-7855            Impact factor:   1.569


  9 in total

1.  Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat.

Authors:  Jean-Daniel Kün-Darbois; Hélène Libouban; Guillaume Mabilleau; Florence Pascaretti-Grizon; Daniel Chappard
Journal:  Clin Oral Investig       Date:  2018-02-16       Impact factor: 3.573

2.  Oral Abundance of Actinomyces spp. in Breast Cancer Patients.

Authors:  Ceren Bilgilier; Thorsten Fuereder; Marie-Theres Kastner; Zoltan Vass; Ingeborg Brandl; Hanka Sahbegovic; Christian F Singer; Christoph Steininger
Journal:  Oncology       Date:  2022-01-20       Impact factor: 3.734

3.  Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis.

Authors:  Jonathan G Messer; Jessica M Jiron; Jorge L Mendieta Calle; Evelyn J Castillo; Ronnie Israel; Ean G Phillips; Joshua F Yarrow; Catherine Van Poznak; Lakshmyya Kesavalu; Donald B Kimmel; J Ignacio Aguirre
Journal:  Oral Dis       Date:  2019-02-19       Impact factor: 3.511

4.  Dental practitioners' and students' knowledge of medication related osteonecrosis of the jaw (MRONJ).

Authors:  Mandlin Abdulaziz Almousa; Ghadah Khalid Alharbi; Amerah Saeed Alqahtani; Yusra Chachar; Lubna Alkadi; Ali Aboalela
Journal:  Saudi Pharm J       Date:  2020-12-29       Impact factor: 4.330

5.  Teledentistry as a Supportive Tool for Dentists in Diagnosing MRONJ in Northern Cyprus.

Authors:  Mujgan Firincioglulari; Kaan Orhan
Journal:  Biomed Res Int       Date:  2021-12-29       Impact factor: 3.411

6.  Suppression of Bone Necrosis around Tooth Extraction Socket in a MRONJ-like Mouse Model by E-rhBMP-2 Containing Artificial Bone Graft Administration.

Authors:  Yukie Tanaka; Kyaw Thu Aung; Mitsuaki Ono; Akihiro Mikai; Anh Tuan Dang; Emilio Satoshi Hara; Ikue Tosa; Kei Ishibashi; Aya Ono-Kimura; Kumiko Nawachi; Takuo Kuboki; Toshitaka Oohashi
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

7.  Use and Evaluation of a Computer-Assisted Examination Method for the Diagnosis and Analysis of Medication-Related Osteonecrosis of the Jaw.

Authors:  Max Wilkat; Daman Deep Singh; Isabelle Lutz; Henriette Möllmann; Nils-Claudius Gellrich; Majeed Rana
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2020-07-15

Review 8.  Medication-related Osteonecrosis of the Jaw: A Review.

Authors:  Nouf A AlDhalaan; Asma BaQais; Ahmad Al-Omar
Journal:  Cureus       Date:  2020-02-10

9.  BMP-2/β-TCP Local Delivery for Bone Regeneration in MRONJ-Like Mouse Model.

Authors:  Akihiro Mikai; Mitsuaki Ono; Ikue Tosa; Ha Thi Thu Nguyen; Emilio Satoshi Hara; Shuji Nosho; Aya Kimura-Ono; Kumiko Nawachi; Takeshi Takarada; Takuo Kuboki; Toshitaka Oohashi
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.